Strategies to enhance N-Methyl-D-Aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

Current Pharmaceutical Design

Volumn 16, Issue 5, 2010, Pages 522-537

  Tsai, Guochuan E ^a,b   Lin, Pao Yen ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SARCOSINE;

ADD ON THERAPY; ADVERSE OUTCOME; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; MENTAL PATIENT; META ANALYSIS; NAUSEA; NEGATIVE SYNDROME; NEUROTRANSMISSION; POSITIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77949447469     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790361452     Document Type: Review

References (95)

1. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165-79.
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
3. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-50.
4. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13:9-19.
5. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
6. Waziri R. Glycine therapy of schizophrenia. Biol Psychiatry 1988; 23: 210-1.
7. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 1989; 12: 416-24.
8. Costa J, Khaled E, Sramek J, Bunney W, Jr., Potkin SG. An open trial of glycine as an adjunct to neuroleptics in chronic treatmentrefractory schizophrenics. J Clin Psychopharmacol 1990; 10: 71-2.
9. Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulasekaram B. Glycine in the treatment of schizophrenia: theory and preliminary results, in Novel Antipsychotic Drugs. In: Meltzer HY, Ed. New York: Raven Press 1992; pp. 179-88.
10. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234-6.
11. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610-7.
12. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol Psychiatry 1996; 39:213-5.
13. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29-36.
14. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156: 145-7.
15. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157: 826-8.
16. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 2001; 4: 385-91.
17. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 165-71.
18. Diaz P, Bhaskara S, Dursun SM, Deakin B. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25: 277-8.
19. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593-602.
20. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081-9.
21. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. Dserine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822-5.
22. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577-85.
23. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59: 230-4.
24. Cascella NG, Macciardi F, Cavallini C, Smeraldi E. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm Gen Sect 1994; 95: 105-11.
25. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995; 152: 1213-5.
26. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628-30.
27. Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol 1996; 19: 444-50.
28. van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996; 40: 1298-300.
29. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmcol 1998; 1: 131-5.
30. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21-7.
31. Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-4.
32. van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 1999; 21: 203-10.
33. Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 2002; 56: 19-23.
34. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 2002; 159: 480-2.
35. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239-48.
36. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, et al. A six-month, placebo-controlled trial of d-cycloserine coadministered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179: 144-50.
37. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
38. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, et al. Glycine transporter I inhibitor, N-methylglycine (Sarcosine) added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-9.
39. Lane HY, Chang YC, Chiu CC, Tsai G. Sarcosine (Nmethylglycine) or D-serine treatment for acutely exacerbated schizophrenia: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2005; 62: 1196-204.
40. Lane HY, Lin YC, Huang CL, Chang YC, Liau CH, Perng CH, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63: 9-12.
41. Lane HY, Lin CH, Huang CL, Chang YC, Liau CH, Tsai GE, A randomized, double-blind, placebo-controlled study of sarcosine (N-methylglycine) and D-serine add-on treatment for chronically stable schizophrenia. Int J Neuropsychopharmacol 2009 Nov 4: 1-10 [Epub ahead of print].
42. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
43. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002; 99: 13675-80.
44. Sacchi S, Bernasconi M, Martineau M, Mothet JP, Ruzzene M, Pilone MS, et al. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem 2008; 283(32): 22244-56.
45. Andreasen NC. Scale for the assessment of negative symptoms. Iowa City, IA: University of Iowa 1983.
46. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia. Initial validation. J Nerv Ment Dis 1994; 182: 631-8.
47. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812.
48. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
49. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
50. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
51. Guy W. ECDEU assessment manual for psychopharmacology, revised ed. Washington, DC: US Department of Health, Education, and Welfare 1976.
52. Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 2005; 10: 275-87.
53. Rosenthal R. Parametric measurements of effect size. In: Cooper H, Hedges LV, Eds. The handbook of research synthesis. New York: Russell Sage foundation 1994; pp. 231-44.
54. Shadish WR, Haddock CK. Combining estimates of effect size. In: Cooper H, Hedges LV, Eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation 1994: pp. 261-81.
55. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
56. Hedges LV. Fixed effects models. In: Cooper H, Hedges LV, Eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation 1994: pp. 285-99.
57. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.
58. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72: 225-34.
59. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003; 1003: 318-27.
60. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-7.
61. Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 2005; 20: 199-205.
62. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT, Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155: 751-60.
63. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506.
64. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
65. Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res 2005; 138: 23-31.
66. Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr Res 2004; 68: 11-9.
67. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36: 35-83.
68. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
69. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163(1): 153-5.
70. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157(10): 1552-62.
71. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 1990; 510: 158-60.
72. Simeon J, Fink M, Itil TM, Ponce D. d-cycloserine therapy of psychosis by symptom provocation. Compr Psychiatry 1970; 11: 80-8.
73. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 1971; 221: 1629-39.
74. Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J Neurosci 1995; 15: 3952-69.
75. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-6.
76. Lechner SM. Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol 2006; 6: 75-81.
77. Keck T, White JA. Glycinergic inhibition in the hippocampus. Rev Neurosci 2009; 20: 13-22. http://www.ncbi.nlm.nih.gov/pubmed/ 19526731?itool= EntrezSystem2.PEntrez.Pubmed.Pubmed-Results Panel.Pubmed- RVDocSum&ordinalpos=1
78. Gabernet L, Pauly-Evers M, Schwerdel C, Lentz M, Bluethmann H, Vogt K, et al. Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. Neurosci Lett 2005; 373: 79-84.
79. Shleper M, Kartvelishvily E, Wolosker H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J Neurosci 2005; 25: 9413-7.
80. McNamara D, Dingledine R. Dual effect of glycine on NMDA-induced neurotoxicity in rat cortical cultures. J Neurosci 1990; 10: 3970-6.
81. Burnet PW, Hutchinson L, von Hesling M, Gilbert EJ, Brandon NJ, Rutter AR, et al. Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr Res 2008; 102: 283-94.
82. Williams JB, Mallorga PJ, Jeffrey CP, Pettibone DJ, Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res 2004; 71(1): 103-12.
83. Woods SW, Walsh BC, Pearlson GD, McGlashan TH. Glycine treatment of prodromal symptoms (abstract). Schizophr Res 2006; 86(suppl 1): S7.
84. Tsai G, Falk W, Gunther G, Coyle JT. D-cycloserine improves cognition of Alzheimer's disease. Am J Psychiatry 1999; 156: 467-9.
85. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002; 5: 301-7.
86. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004; 161: 2115-7.
87. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62: 835-8.
88. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-44.
89. Lee SY, Chan KY, Chan AY, Lai CK. A report of two families with sarcosinaemia in Hong Kong and revisiting the pathogenetic potential of hypersarcosinaemia. Ann Acad Med Singapore 2006; 35: 582-4.
90. Hikida T, Mustafa AK, Maeda K, Fujii K, Barrow RK, Saleh M, et al. Modulation of D-serine levels in brains of mice lacking PICK1. Biol Psychiatry 2008; 63: 997-1000.
91. Sacchi S, Bernasconi M, Martineau M, Mothet JP, Ruzzene M, Pilone MS, et al. pLG72 modulates intracellular D-Serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibiliy. J Biol Chem. 2008; 283: 22244-56.
92. Rutter AR, Fradley RL, Garrett EM, Chapman KL, Lawrence JM, Rosahl TW, et al. Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur J Neurosci 2007; 25: 1757-66.
93. Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008; 14(15): 1512-24.
94. Miller CL. The evolution of schizophrenia: a model for selection by infection, with a focus on NAD. Curr Pharm Des 2009; 15(1): 100-9.
95. Penberthy WT. Nicotinamide adenine dinucleotide biology and disease. Curr Pharm Des 2009; 15(1): 1-2.